Situgen
order online
order options
contact us
Home Company Product FAQ How to contact us Ask A Question Contact us
 
  Israeli stem cell device lengthens the cord that save lives
 

 


 

Israeli stem cell device lengthens the cord that save lives


 

Category Cord Blood Banking
Posted on 2/27/2006 10:22:00 AM
 


 

Umbilical cord blood stem cells are used to treat and save more lives than ever before.

The umbilical cord is not just a baby''s lifeline until birth, but has also been proven to be a vital source of stem cells to treat life-threatening illnesses such as leukemia, cerebral palsy and brain injury - for the child itself, its adult family members and others. However, current methods used to extract the blood by the several dozen cord blood banks in the US are severely restricted by the fact that they can only extract enough blood to treat someone weighing up to 45kg (100 pounds).

BioCord, an Israeli start-up, has developed a novel method for collecting more than double this amount of blood from the umbilical cord, which means more illnesses can be treated and potentially more lives saved.

Their SituGen self-contained system does away with the current method of extracting the blood using a needle, which limits the amount of blood able to be extracted.

Storing cord blood is becoming more common in the US and worldwide since the first cord blood transplant in 1988. The blood is taken from the umbilical cord after the baby has been delivered and the cord cut and clamped but before the placenta emerges. Parents can pay to have the cord blood stored in a private cord blood bank, kept for their child and family members, or donate it anonymously to a public cord blood bank.

"Stem cells are taken from the cord blood and stored frozen in liquid nitrogen," explains Miki Shacham, the CEO of Ramat-Gan-based Israeli cord blood bank BioCord and the inventor of the new device. "These are first of all for the baby itself, they are a one hundred percent match. But there is a high probability of a match with close family members."

Stem cells are commonly taken from the bone marrow to treat diseases such as leukemia, but these stem cells are already mature; cord blood stem cells are much less mature, only nine months old, which means, says Shacham, "that they are more primitive and so they can become all types of cells," useful for treating a variety of diseases, not just illnesses of the blood.

There are around 80 illnesses that are now being treated with these stem cells, Shacham told ISRAEL21c. The young age of the cord blood stem cells also means a lower match is needed with the donor cells to receive a stem cell transplant, compared with bone marrow stem cells. Embryonic stem cells are even younger and therefore more flexible, but harvesting embryonic stem cells is highly controversial in most countries worldwide.

The current method for extracting cord blood involves inserting a needle into the vein of the umbilical cord, and, keeping the placenta higher than the cord so that gravity pulls the blood downwards, the blood flows into a bag or a syringe, with the collector taking care not to contaminate it with the mother''s blood or bacteria from outside. However, although a skilled collector may be able to extract more, this method usually collects around 80 milliliters of the maximum 250 ml of blood generally present in the cord. There are roughly 80 to 100 million stem cells in 80ml, enough for someone who weights up to 100 pounds, a large child or a small adult.

"The major problem of cord blood banks is the amount of blood that is extracted," says Shacham, an engineer who also holds an MBA. He decided to see what could be done.

The members of the R&D group headed by Shacham, which include stem cell pioneer Prof. Joseph Itzkoviz of the Rambam Medical Center''s department of obstetrics and gynecology in Haifa, Prof. Arnon Nagler of Tel Hashomer''s hematology department, Prof. Alexander Batler, head of cardiology at the Clalit health fund, and hematologist Prof. Eliezer Rachmilewitz, discovered that the problem lay in what happens to the blood a few minutes after birth.

"During clinical tests we collected [cord] blood, left it to stand for five minutes and then tried to pour it out," says Shacham. But it wouldn''t pour - because it had already started thickening, or coagulating. "This starts happening minutes after birth [inside the cord]," he says. "With the current collection method used world-wide, you''re trying to extract the blood [with a needle] and it has already half-coagulated. It''s amazing how fast it happens. That is the problem and nobody recognized it. We now know that all those that were trying to solve the problem [of extracting more blood] were all wrong at the same point, they were making the same mistakes and assumptions."

The half-millimeter needle that is inserted into the vein, which is several millimeters wide, simply can''t quickly and freely enough extract all the thickening blood. So Shacham and his team developed the SituGen which does away with the needle entirely.

Made mainly of polypropylene and latex, the SituGen comprises a holder which clamps around the umbilical cord, holding the cord in place as the placenta is delivered and absorbing the ma
 

Previous page  Top  Next page  Contact us/ Ask question